Sjogren'
Conditions
Interventions
Mizoribine 10 mg/kg (up to 500 mg) will be administered once daily twice a week.
Sponsors
Graduate School of Medicine, Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with primary Sjogren's syndrome fulfill the revised diagnostic criteria for Sjogren's syndrome of the Ministry of Health and Welfare (1999)
Exclusion criteria
Exclusion criteria: 1. Patients with a history of mizoribine use 2. Patients with a white blood cell count of not more than 3,000 / mm3 3. Pregnant women or women who may become pregnant and women who wish to become pregnant during the course of the study 4. Patients who used cevimeline hydrochloride hydrate, pilocarpine hydrochloride and anetholtrithion within the 4 week period before the start of the study 5. Patients using other immunosuppressive drugs and anti-rheumatoid drugs 6. Other patients who were judged to be ineligible for the study by an attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of saliva production Change of data of laboratory examinations | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of salivary function, change of subjective symptoms, change of data of laboratory examinations, gastrointestinal symptoms | — |
Countries
Japan
Contacts
Public ContactMinako Tomiita
Graduate School of Medicine, Chiba Universitity Department of Pediatrics
Outcome results
None listed